The US Healthcare Environmental Services Market is set to experience substantial growth, with an anticipated value of USD 8.7 billion by 2026, as per a recent report. This market, which was valued at USD 6.6 billion in 2021, is expected to grow at a CAGR of 5.8% during the forecast period. The surge in growth can be attributed to stringent government regulations and the increasing prevalence of Hospital-Acquired Infections (HAIs).

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=205929082

The COVID-19 pandemic has had a profound impact on healthcare systems globally, with hospitals overwhelmed due to the increasing number of patients. To cope with this surge, temporary hospitals have been set up, further necessitating enhanced environmental services. Consequently, there has been a surge in demand for disinfection and infection prevention services, particularly due to the growing cases of HAIs in hospital settings. Responding to hospital-acquired infections has become a critical medical issue worldwide during the pandemic. Therefore, the overwhelming adoption of strict measures to reduce infection spread, coupled with government mandates, is expected to drive the growth of the healthcare environmental services market.

Janitorial/Core-Cleaning Services: Leading the Market Growth

The janitorial/core-cleaning services segment is expected to be the fastest-growing segment during the forecast period. This growth is primarily due to the need for regular cleaning and maintaining the cleanliness of health facility premises to prevent the spread of infection among patients and staff.

Acute-Care Facilities: Major Market Shareholders

The acute-care facilities segment accounted for the largest share of the US healthcare environmental services market in 2020. The growth of this segment can be attributed to the increasing adoption of various outsourced cleaning services. These services have helped acute-care facilities reduce in-house administrative costs, such as the buying and maintenance costs of various cleaning technologies and supplies.

Key Players in the Market

Some of the prominent players operating in the US healthcare environmental services market include:

1. Sodexo Global (France)
2. Compass Group (UK)
3. Aramark Corporation (US)
4. Hospital Housekeeping Systems, Inc. (HHS) (US)
5. ABM Industries Incorporated (US)
6. Xanitos, Inc. (US)
7. OctoClean Franchising Systems, Inc. (US)
8. AVI Foodsystems, Inc. (US)
9. Jani-King International, Inc. (US)
10. Healthcare Services Group, Inc. (US)
11. ServiceMaster Clean (US)
12. Bravo Building Services (US)
13. Corvus Janitorial Systems (US)

These players are making significant contributions to the market by offering a wide range of environmental services catering to the evolving needs of healthcare facilities.

Request Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=205929082

In conclusion, the US healthcare environmental services market is poised for substantial growth, driven by the increasing focus on infection control and the rising demand for enhanced cleaning and disinfection services in healthcare facilities. As the importance of maintaining a sterile environment becomes more critical, these services will play an increasingly pivotal role in safeguarding the health and safety of patients and staff.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

According to a recent report the pain management devices market is projected to reach USD 3.3 billion by 2026, growing at a compound annual growth rate (CAGR) of 8.6%. This remarkable growth can be attributed to several key factors driving the market’s expansion.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=91418163

Increasing Patient Population and Demand for Long-Term Pain Management

The aging global population and the rising prevalence of conditions such as cancer, neurological disorders, and musculoskeletal issues have contributed to the growing demand for pain management devices. These devices offer long-term pain relief solutions, improving the quality of life for patients suffering from chronic pain.

Preference for Devices over Oral Pain Medications

Many patients and healthcare professionals are increasingly favoring pain management devices over traditional oral pain medications. This preference stems from the adverse effects often associated with prolonged use of pain medications, such as dependency and potential organ damage. Pain management devices provide a more targeted and sustainable approach to pain relief.

Technological Advancements and Novel Device Development

Continuous research and development in the field of pain management have led to the introduction of innovative devices with improved efficacy and enhanced patient comfort. Neurostimulation devices, such as spinal cord stimulators and transcutaneous electrical nerve stimulators (TENS), are among the most significant advancements in this market.

Established Reimbursement Scenarios in Developed Countries

In developed countries, favorable reimbursement policies for pain management devices, particularly for spinal cord stimulators, have played a crucial role in driving market growth. These policies have made these devices more accessible to patients, further fueling market expansion.

Market Segmentation and Growth Opportunities

The pain management devices market can be segmented based on device type, application, mode of purchase, and region.

Neurostimulation devices, including spinal cord stimulators and TENS, held the largest market share in 2020 at 58%. The high efficacy, long-term cost-effectiveness, and technological advancements in this segment contribute to its dominant position.

Regarding applications, the neuropathic pain segment accounted for the largest market share of 31.4% in 2020. The growing aging population, clinical evidence supporting the efficacy of these devices for neuropathic pain, and the availability of reimbursement have driven the adoption of pain management devices in this segment.

Geographically, North America dominated the pain management devices market in 2020 and is expected to continue its lead during the forecast period, with a projected CAGR of 7.3%. The region’s advanced healthcare infrastructure, presence of major market players, and increasing incorporation of pain management devices in ambulatory care centers have contributed to its market dominance.

Key Players and Market Dynamics

The pain management devices market is highly competitive, with several prominent players operating globally. Major companies in this space include Medtronic PLC, Boston Scientific, Abbott, Becton, Dickinson and Company, Baxter International, B. Braun Melsungen AG, Stryker, Smiths Medical, and Moog Inc., among others.

While the market presents significant growth opportunities, it also faces challenges. The COVID-19 pandemic caused disruptions in the market due to restrictions on screening, diagnostic exams, and surgical procedures at hospitals and cancer care centers. Additionally, unfavorable regulatory changes and guidelines have hampered market growth to some extent.

Request For Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=91418163

Conclusion

The global pain management devices market is experiencing significant growth driven by increasing patient populations, demand for long-term pain management solutions, and technological advancements. As healthcare providers and patients seek effective alternatives to oral pain medications, the adoption of these devices is likely to continue its upward trajectory. With ongoing research and development, the market is poised to introduce even more innovative and efficient pain management solutions in the coming years.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

The monoclonal antibody therapeutics market is poised for robust growth, with the market projected to reach USD 497.5 billion by 2029 from an estimated USD 252.6 billion in 2024. This represents a compound annual growth rate (CAGR) of 14.5% during the forecast period. The growth of this market is driven by the increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and infectious diseases, as well as advancements in antibody engineering and production processes.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=115323820

Market Segmentation and Trends

Production Method

The monoclonal antibody therapeutics market is segmented based on production methods into in vitro and in vivo. In 2023, in vitro production accounted for the largest share of the market due to its scalability, cost-effectiveness, and lower risk of contamination compared to traditional in vivo methods. Additionally, advancements in cell culture and bioprocessing techniques have enhanced productivity and consistency.

Sources

Based on sources, the market is segmented into human, humanized, chimeric, and other sources. In 2023, the human segment accounted for the largest share of the market. The human source segment is expected to grow at a higher rate during the forecast period of 2024-2029 due to its reduced immunogenicity, improved efficacy, and enhanced safety profiles compared to non-human sources. Notable drugs include adalimumab (Humira) for autoimmune diseases and pembrolizumab (Keytruda) for cancer.

Therapy Areas

The market is segmented based on therapy areas into autoimmune and inflammatory disorders, oncology, hematology, ophthalmology, and other therapy areas. In 2023, the autoimmune and inflammatory diseases segment accounted for the largest share of the market, driven by the increasing prevalence of these diseases and advancements in targeted therapies. For instance, adalimumab (Humira) is widely used for treating rheumatoid arthritis, while infliximab (Remicade) is used for Crohn’s disease.

Regional Insights

North America

North America dominated the monoclonal antibody therapeutics market due to its robust healthcare infrastructure and high prevalence of chronic diseases. The region is home to many leading pharmaceutical companies investing heavily in research and development.

Europe

Europe is expected to grow at a significant CAGR during the forecast period, driven by a combination of favorable government policies, research and development investments, and rising prevalence of chronic diseases. The region’s strong healthcare infrastructure and collaborations between academia, industry, and regulatory bodies further contribute to its growth.

Asia Pacific

The Asia Pacific region is also expected to witness substantial growth during the forecast period due to rising healthcare spending, increased awareness about advanced therapies, and expanding access to healthcare services.

Key Market Players

The monoclonal antibody therapeutics market is characterized by the presence of leading players, including:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• AbbVie Inc. (US)
• Johnson & Johnson Services, Inc. (US)
• Merck & Co., Inc. (US)
• Bristol Myers Squibb Company (US)
• AstraZeneca (UK)
• Sanofi (France)
• Novartis AG (Switzerland)
• Amgen Inc. (US)
• Takeda Pharmaceutical Company Limited (Japan)
• GSK plc. (UK)
• Eli Lilly and Company (US)
• Regeneron Pharmaceuticals Inc. (US)

These key players are focusing on expanding their product portfolios, engaging in strategic collaborations, and investing in research and development to maintain their competitive edge in the market.

Request Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=115323820

Conclusion

The monoclonal antibody therapeutics market is set to experience strong growth in the coming years due to the increasing prevalence of chronic diseases, technological advancements, and expanding applications in personalized medicine. The future holds immense potential for this market, as innovations in antibody engineering and targeted therapies continue to advance patient outcomes across various medical conditions.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

According to research report the global minimal residual disease testing market is projected to reach USD 2.3 Billion by 2027, at a CAGR of 14.0%. Increasing prevalence of cancer and hematological malignancies, rising initiatives undertaken by government bodies to create awareness about cancer, and increasing collaborations are factors driving the growth of the global minimal residual disease testing market. Emerging economies such as China, Japan, and India are providing lucrative opportunities for the players operating in the minimal residual disease testing market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=215386038

The PCR segment accounted for the largest share of the minimal residual disease testing market, by technology segment, in 2021

Based on technology, the minimal residual disease testing market is segmented into flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS). The polymerase chain reaction technology segment accounted for the largest share in 2021. The large share of this segment is due to the device being easy to use, being easily available with relative sensitivity and cost efficiency.

Hematological Malignancies segment to register the highest growth rate during the forecast period

Based on applications, the minimal residual disease testing market is segmented into hematological malignancies, solid tumors, and other applications. In 2021, the hematological malignancies segment accounted for the largest share primarily due to factors such as the increasing incidence of leukemia and lymphoma and the need to continuously monitor the patients with these diseases.

The hospitals & specialty clinics accounted for the largest share of the minimal residual disease testing market, by end user segment, in 2021

Based on end users, the minimal residual disease testing market has been segmented into hospitals & specialty clinics, diagnostic laboratories, academic & research institutes, and other end users. In 2021, the hospitals & specialty clinics segment accounted for the largest share of this market, due to availability of advanced diagnostic devices with skilled and professional healthcare workforce.

North America is the largest regional market for minimal residual disease testing market

The global minimal residual disease testing market has been segmented into four major regions—North America, Europe, the Asia Pacific, Latin America and Middle East and Africa. North America accounted for the largest share of the minimal residual disease testing market. The large share of this regional segment can be attributed to the growing incidence of hematological malignancies which include leukemia and lymphoma, well-developed healthcare systems in the US and Canada, the presence of many leading clinical laboratories across nation, and the easy availability of advanced diagnostic instruments.

Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=215386038

The major players operating in this market are Labcorp Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland),  Guardant Health (US), Sysmex Corporation (Japan), NeoGenomics Laboratories, Inc. (US), Adaptive Biotechnologies Corporation (US), ArcherDX, Inc. (US), Asuragen Inc. (US), Arup Laboratories Inc. (US), Bio-Rad Laboratories, Inc. (US), Cergentis B.V. (Netherlands), Molecular MD (ICON plc) (Ireland), Invivoscribe, Inc. (US), Mission Bio, Inc. (US), Natera, Inc. (US), Opko Health, Inc. (US), Quest Diagnostics (US), and Genetron Health (China), among others.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

According to research report the Hyperspectral Imaging Systems Market is projected to soar from USD 16.8 billion in 2023 to an estimated USD 34.3 billion by 2028, growing at a compelling CAGR of 15.4% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=246979343

Key Factors Driving the Market Growth

The robust growth of the Hyperspectral Imaging Systems Market can be attributed to several key factors:

1. Government Funding in Defense: The escalating defense funding by governments worldwide has played a pivotal role in driving market growth. Hyperspectral imaging systems are indispensable for military applications, including target detection, surveillance, and reconnaissance. Governments recognize the strategic significance of these systems, leading to increased investments in research and development.
2. Expanding Applications: The versatility of hyperspectral imaging systems is another driving force. These systems find applications in diverse sectors, such as agriculture, environmental monitoring, machine vision, and life sciences & diagnostics. As industries continue to adopt hyperspectral imaging technology, demand for these systems continues to rise.
3. Technological Advancements: Continuous technological advancements have enhanced the capabilities and reduced the costs of hyperspectral imaging systems. This makes them more accessible to a broader range of industries and applications, further fueling market growth.

Segmentation of the Hyperspectral Imaging Systems Market

1. Product Segmentation: The market comprises various products, including cameras and accessories. Cameras are at the forefront of this segment, owing to their pivotal role in capturing hyperspectral images with precision.
2. Technology Segmentation: Hyperspectral imaging systems are available in two primary technologies: snapshot and pushbroom. Snapshot technology captures an entire hyperspectral image in a single snapshot, whereas pushbroom technology acquires data through a continuous scanning process.
3. Application Segmentation: The market serves multiple applications, including:
   • Military: Hyperspectral imaging systems are extensively used for defense purposes, including target identification, camouflage detection, and surveillance.
   • Remote Sensing (Agriculture and Environmental): In agriculture, these systems aid in crop monitoring, disease detection, and yield optimization. In environmental applications, they assist in monitoring land use, pollution, and natural resource management.
   • Machine Vision: Industries use hyperspectral imaging for quality control, defect detection, and material analysis.
   • Life Sciences & Diagnostics: In the healthcare sector, hyperspectral imaging plays a crucial role in disease diagnosis, tissue analysis, and pharmaceutical research.

North America dominates the global hyperspectral imaging systems market

Based on the region, the hyperspectral imaging systems market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The North American market is driven by the rising adoption of hyperspectral imaging in military surveillance and, life sciences & medical diagnostics. Europe is the second-largest market for hyperspectral imaging systems, characterized by rising awareness of the benefits of hyperspectral imaging, and the growing demand for hyperspectral data acquisition for building application libraries are the major factors driving the market in Europe.

Download Free Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=246979343

Conclusion

The Hyperspectral Imaging Systems Market is poised for remarkable growth in the coming years. Driven by increasing government funding, expanding applications, and ongoing technological advancements, it offers a plethora of opportunities for both businesses and industries. As hyperspectral imaging systems continue to evolve and find new applications, their relevance in diverse sectors will only grow stronger, further propelling the market toward the projected USD 34.3 billion mark by 2028. Businesses and investors keen on capitalizing on this growth should keep a close eye on this burgeoning market.

In conclusion, the Hyperspectral Imaging Systems Market is a testament to the transformative power of advanced imaging technology and its immense potential to reshape industries and drive innovation in the years to come.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

The global defibrillator market is experiencing remarkable growth, driven by the rising incidence of cardiac arrest among patients with cardiovascular diseases worldwide. This crucial medical equipment has become a beacon of hope, aiding in the prompt response during cardiac arrest emergencies. The market is anticipated to reach USD 18.1 billion by 2028 from USD 13.6 billion in 2023, reflecting a CAGR of 5.9% during the forecast period. Several factors, such as increased defibrillator installation in public access areas, extensive training and awareness programs, and continuous advancements in defibrillator technology, are contributing to this growth. In this article, we delve into the key drivers, major players, and their strategies in the defibrillator market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=549

Factors Driving the Defibrillator Market

1. Cardiovascular Disease Prevalence: The global rise in cardiovascular diseases is a major catalyst for the defibrillator market. An increasing number of patients are at risk of cardiac arrest, necessitating the availability of defibrillators for timely intervention.
2. Installation in Public Places: Governments and private organizations are actively promoting the installation of defibrillators in public areas, such as airports, shopping malls, and schools. This initiative enhances the chances of rapid response during emergencies, ultimately saving lives.
3. Training and Awareness Programs: The importance of defibrillator training and awareness cannot be overstated. As more people become educated on how to use defibrillators, they become better equipped to assist in cardiac emergencies.
4. Technological Advancements: Ongoing developments in Subcutaneous Implantable Cardioverter Defibrillators (S-ICDs), as well as MRI-compatible ICDs & CRT-Ds, are enhancing the effectiveness and safety of defibrillators.
5. Healthcare Infrastructure Improvements: Emerging nations are investing in improving their healthcare infrastructure, increasing the accessibility of defibrillators and ensuring better healthcare outcomes.

Major Players in the Defibrillator Market

1. Medtronic (Ireland): Medtronic is a global leader in the implantable defibrillator market, offering an extensive product portfolio dedicated to managing heart failure and heart rhythm disorders. The company is known for its innovative product development and inorganic growth strategies. In 2023, Medtronic received the CE Mark for its implantable defibrillator systems, demonstrating its commitment to advancing the field. Furthermore, Medtronic is expanding its research and development capabilities, focusing on product development and commercialization in both mature and emerging markets.
2. Stryker (US): Stryker is a key player in the defibrillator market, known for its comprehensive product offerings. The company excels in product launches, acquisitions, and partnerships to expand its presence. By continuously introducing new and improved defibrillator technologies, Stryker remains at the forefront of the industry.
3. Koninklijke Philips (Netherlands): Koninklijke Philips N.V. is a prominent player in the external defibrillators market. The company prioritizes expansion through acquisitions, collaborations, agreements, and partnerships. In 2022, Philips acquired Cardiologs, a medical technology company specializing in cardiac diagnostics, and partnered with Life-Assist, Inc. and Mackenzie Health to supply and install defibrillators in public places. These strategic moves have amplified Philips’ reach and customer base in the defibrillators market.
4. Asahi Kasei Corporation (Japan): Asahi Kasei Corporation is a significant contributor to the defibrillator market. The company emphasizes research and development to offer innovative solutions in the field of defibrillation. With a focus on technological advancements, Asahi Kasei continues to make a substantial impact in the market.
5. Boston Scientific Corporation (US): Boston Scientific is a key player with a strong presence in the global defibrillator market. The company’s commitment to product development and partnerships enables it to meet the evolving demands of the market effectively.
6. Abbott (US): Abbott is a major player in the defibrillator market, continuously innovating to improve patient outcomes. The company’s growth is driven by its emphasis on product development and commercialization, ensuring it maintains a competitive edge.

Request Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=549

The defibrillator market is poised for substantial growth, with the potential to save countless lives. The collaboration of global players, including Medtronic, Stryker, Koninklijke Philips, Asahi Kasei Corporation, Boston Scientific Corporation, and Abbott, in developing cutting-edge technologies and expanding their reach, underscores the importance of defibrillators in healthcare. As cardiovascular diseases continue to affect individuals worldwide, the defibrillator market remains at the forefront of ensuring swift and effective intervention during cardiac emergencies. With ongoing advancements and an increased focus on training and awareness, the future of the defibrillator market looks promising.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

The global spinal implants market is projected to reach USD 14.3 billion by 2028 from USD 11.2 billion in 2023, growing at a CAGR of 5.0% during the forecast period. Spinal disorders, such as herniated discs, fractures, stenosis, and degenerative disc diseases, are on the rise globally. Spinal implants are pivotal in hospitals and orthopedic centers, offering advanced and accurate surgery technologies for healthcare providers. The rising incidence of spinal disorders globally is driving the demand for spinal implants market. Advancements in spine surgery technologies, rising demand for minimally invasive surgical procedures, and Increasing regulatory support to manage spinal disorders in healthcare are a few drivers that collectively contribute to the growth of the spinal implants market, and as spine surgery technologies continue to evolve, the demand for spinal implants is expected to rise further in the coming years with more sensitive and specific minimally invasive spine surgical procedures by enhancing accuracy. However, Cost constraints can limit access, especially in regions with limited healthcare budgets and market growth.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=712

The spinal implants market is intensely competitive, with several established players and new entrants vying for market share. The competition in the spinal implants market is driven by factors such as growth in the aging population, product innovation, pricing strategies, distribution networks, and regulatory compliance. Here are some of the key players in the spinal implants market. Medtronic plc (Ireland), Johnson & Johnson (Depuy Synthes) (US), Stryker Corporation (US), NuVasive (US), Globus Medical Inc. (US), Zimmer Biomet Holdings (Warsaw), RTI Surgical Inc. (US) and Spineart (Switzerland).

Medtronic PLC (Ireland): Medtronic PLC is a prominent player in the spinal implants market and has a significant presence in various product segments. The company offers a range of spinal implants designed for various spine surgical procedures. Medtronic maintains a pioneering position in spinal implants through strategic investments in cutting-edge research and development initiatives. These investments are directed toward enhancing the safety, specificity, and efficiency of its spinal implant products.

Medtronic is involved not only in hardware but also in the development of biologics, including bone graft technologies. This comprehensive approach addresses both the structural and biological aspects of spinal surgery. Medtronic’s spinal division has a global presence, making its spinal implants widely accessible across different regions.

Johnson & Johnson ( Depuy Synthes) (US): Johnson & Johnson, through its subsidiary DePuy Synthes, has a significant presence in the spinal implants market. The company offers a comprehensive portfolio of spinal implants and devices. This includes products for cervical and lumbar fusion, minimally invasive procedures, and solutions for addressing various spinal disorders.

The company consistently allocates significant resources to the advancement of cutting-edge technologies and surgical techniques. DePuy Synthes has shown a focus on minimally invasive solutions for spinal surgeries. This aligns with the industry trend towards less invasive procedures, offering benefits such as reduced recovery time and minimized tissue disruption.

It has a strong presence in the spinal implants market that can be attributed to its extensive research and development efforts, strategic acquisitions, and collaborations with various healthcare providers.

Asia-Pacific is expected to be the highest CAGR during the forecast period.

The spinal implants market is divided into key regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America held the largest market share in the global market. However, the Asia Pacific region is anticipated to exhibit the highest Compound Annual Growth Rate (CAGR) during the forecast period. This growth is primarily attributed to the demographic shift with a rapidly aging population, a rise in healthcare budgets and investing in healthcare infrastructure. This includes advancements in surgical techniques and the adoption of advanced spinal implants. Additionally, the market in the Asia Pacific region is set to receive a boost from the growing number of local manufacturers offering spinal implants products and the increasing establishment of healthcare facilities for spinal surgeries with implants in the area.

Request Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=712

As of 2022, prominent players in spinal implants market are Medtronic plc (Ireland), Johnson & Johnson (Depuy Synthes) (US), Stryker corporation (US), NuVasive (US), Globus Medical Inc. (US), Zimmer Biomet holdings (Warsaw), RTI Surgical Inc. (US), Spineart (Switzerland), Boston Scientific Corporation (US), Abbott Laboratories (US) among several others.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

According to research report the global Healthcare IT Integration Market is poised for robust growth in the coming years as healthcare providers increasingly seek to connect disjointed systems and aggregate patient data across care settings. According to MarketsandMarkets Research, the global market was valued at $3.9 billion in 2021 and is projected to reach $7.1 billion by 2026, expanding at a compound annual growth rate (CAGR) of 12.4%.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=228536178

Several macro trends are driving spending on IT integration solutions. The widespread adoption of electronic health records (EHRs) and other digital tools has created a pressing need to integrate data locked in departmental silos. Additionally, the COVID-19 pandemic accelerated the use of telehealth and remote monitoring, which rely heavily on system and device interoperability. Favorable government policies and funding programs also incentivize the meaningful use of integrated health IT infrastructure.

However, substantial barriers to large-scale integration initiatives remain. Interoperability issues abound due to the lack of universal data standards across proprietary health IT systems and medical devices. Such projects also entail high upfront software, hardware, training, and consulting costs. Privacy and security concerns around connecting multiple data sources further contribute to inertia.

Nonetheless, the growing data volume and complexity in healthcare underscore the urgent need for system-agnostic aggregation and analysis. Market leading EHR, telehealth and health information exchange platform vendors are rapidly incorporating integration-focused capabilities through development and acquisitions. The market for interface and integration engines that enable data flow across otherwise siloed applications is also expanding quickly.

Among product and service segments, implementation and integration services command the highest market share given the custom nature of each provider’s IT environment. Support and maintenance additionally see strong demand to smooth interoperability and provide upgrades. Growth rates are projected to be highest for medical device integration software that bridges critical care devices with data repositories.

Hospitals are currently the dominant end user segment as large integrated delivery networks attempt to create unified patient health records across their ambulatory clinics and inpatient facilities. Home healthcare, pharmacies and other remote care settings will likely exhibit high adoption rates thanks to the enablement of telemedicine and remote monitoring tools.

On a geographic basis, North America claims the majority stake in the global healthcare IT integration solutions market, aided by strict interoperability guidelines and financial incentives to digitize health data under laws like HITECH. But emerging economies are displaying robust growth as incomes, health awareness and insurance improve. Local integration solution providers also see opportunities to compete.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=228536178

In summary, the imperative to break down data silos and enable whole-person care presents a multi-billion-dollar opportunity for healthcare IT integration over the next five years. Market dynamism will likely persist as new technologies and health data sources continuously emerge.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

The latest report titled “Immunohistochemistry Market by Product (Antibodies, Reagents, Equipment, Kits), Application (Diagnostics [Cancer, Infectious, Autoimmune Diseases], Research, Forensic), End Users (Diagnostic laboratories, Research Institute) – Global Forecast to 2028″ projects significant growth in the global immunohistochemistry market. According to the report, the market is anticipated to reach USD 4.7 billion by 2028, up from USD 3.2 billion in 2023, reflecting a notable CAGR of 7.4% during the forecast period of 2023 to 2028.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121632939

The driving forces behind this growth include several key factors. Firstly, the increase in the geriatric population and the consequent rise in cancer cases globally have significantly contributed to market expansion. Secondly, technological advancements in Immunohistochemistry (IHC) have enhanced its diagnostic capabilities, making it an increasingly preferred method across various medical applications. Furthermore, the availability of reimbursements for IHC tests has facilitated broader adoption.

However, despite the positive outlook, certain factors may impede market growth. The presence of alternative tests and the significant market consolidation by major players are expected to pose challenges during the forecast period.

Opportunity: Growing significance of companion diagnostics

Companion diagnostics include tests or assays intended to assist healthcare providers in making treatment decisions for patients based on the best response to therapy. The co-development of companion diagnostics with therapeutic products has the potential to significantly alter the drug development process and commercialize drug candidates by yielding safer drugs with enhanced therapeutic efficacy quickly and cost-effectively. With an increase in the demand for high-priced specialist therapies and safer drugs, the market for companion diagnostics has a high growth potential. The growing importance of companion diagnostics is also providing growth opportunities for the diagnostics segment and, in turn, the IHC market. Recently, In October 2022, Roche received approval by US FDA for first IHC based companion diagnostic for PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify metastatic breast cancer patients with low HER2 expression for whom Enhertu (fam-trastuzumab deruxtecan-nxki). Pharmaceutical companies are increasingly collaborating with diagnostic companies to make safer and more effective drugs. For instance, in January 2023, Thermo partnered with AstraZeneca to Develop Solid Tissue and Blood-Based Companion Diagnostic Test for Tagrisso. Also, in January 2020, Amgen entered into strategic collaborations with Guardant Health, Inc. (US) and QIAGEN (Germany) to develop blood- and tissue e-based companion diagnostics (CDx), for investigational cancer treatment AMG 510. Such development for companion diagnostics and the integration of companion diagnostics with IHC is facilitating personalized medicine, supporting drug development and approval processes, expanding market potential, improves patient outcomes, encouraging research collaboration, and providing growth opportunities for Immunohistochemistry Market.

The report highlights the remarkable growth in the Kits product segment within the immunohistochemistry market. In 2022, this segment witnessed the highest growth rate, attributed to the growing demand for comprehensive solutions from single, reliable providers. Ready-to-use kits streamline the IHC process, eliminating the time-consuming selection of primary antibodies and stains, thus fostering market growth.

In terms of applications, while diagnostic and research segments dominate the market, the forensic application segment accounted for the smallest share in 2022. Although IHC plays a crucial role in forensic pathology, particularly in determining the cause of death, its applications are limited due to tissue degradation post-mortem.

Among end users, hospitals and diagnostic laboratories represent the largest segment, driven by the increasing number of specialty diagnostic tests and the rising trend of in-house diagnostic capabilities. The Asia-Pacific region emerges as the fastest-growing market, propelled by economic growth, rising chronic diseases prevalence, increasing healthcare spending, and government initiatives promoting healthcare awareness and accessibility.

Request Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=121632939

Key players in the global immunohistochemistry market include F. Hoffman-La Roche AG, Danaher Corporation, and Agilent Technologies, Inc.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

The global single use consumables market is set to witness remarkable growth, reaching a projected value of USD 4.7 billion by 2027, up from USD 2.2 billion in 2022, according to the latest report titled “Single Use Consumables Market” by [Market Research Firm]. This surge represents a robust compound annual growth rate (CAGR) of 16.6%.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=44374840

The report delves into various aspects of the single-use consumables market, analyzing key products, applications, end-users, and regional dynamics driving this growth trajectory. With 261 market data tables, 32 figures, and an in-depth table of contents, the report offers comprehensive insights into this burgeoning industry.

Rising Adoption of Single-Use Bioprocessing

One of the primary drivers of this market growth is the increased adoption of single-use bioprocessing techniques by pharmaceutical players in their production processes. The convenience, cost-effectiveness, and scalability offered by single-use consumables have propelled their uptake across various end-user segments. The market is witnessing a surge in user-friendly and budget-friendly products, further stimulating adoption rates and indicating promising growth prospects in the forthcoming years.

Tubing Segment Leads the Market

In 2021, the tubing segment emerged as a frontrunner in the single-use consumables market, holding a significant share. The report segments single-use consumables into various products, including tubing, connectors, disconnectors, adapters, valves, disposable capsule filters, and single-use sensors. Among these, tubing stands out as the largest and fastest-growing segment. It encompasses tubing assemblies and components, with variations in material (silicone, elastomer, and others) and type (assemblies and components). The connectors segment is also poised for rapid growth, driven by increased usage and the introduction of innovative products.

Filtration Applications Drive Market Dominance

Filtration applications dominated the global single-use consumables market in 2021, boasting the largest share. Single-use filtration consumables offer several advantages over traditional stainless steel consumables, including quicker equipment turnover for new products, reduced testing and cleaning time, and enhanced production flexibility. These advantages have propelled the adoption of filtration applications, contributing significantly to market growth.

Regional Insights: North America Leads, Asia Pacific Shows Promise

Geographically, North America emerged as the dominant region in the single-use consumables market in 2021, driven by the presence of key market players and increasing public-private initiatives for research activities. However, the Asia Pacific region is poised to exhibit the highest CAGR during the forecast period. Factors fueling this growth include the burgeoning pharmaceutical industry, rising adoption of single-use consumables in research, expansion of research infrastructure, and industrial initiatives aimed at advancing research capabilities in the region.

Key Players Driving Innovation

Prominent players in the single-use consumables market include Thermo Fisher Scientific, Inc. (US), Sartorius Stedim Biotech (France), Danaher Corporation (US), Merck KGaA (Germany), and Avantor, Inc. (US). These companies have adopted both organic and inorganic growth strategies, such as product launches and acquisitions, to maintain their leading positions in the market.

Request Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=44374840

Conclusion

The single use consumables market is on a trajectory of substantial growth, driven by factors such as increased adoption of single-use bioprocessing, product innovation, and expanding applications across diverse end-user segments. With North America leading the charge and the Asia Pacific region showing immense promise, the market presents lucrative opportunities for both established players and new entrants.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]